Related Experiment Video
Updated: May 10, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
Biotherapeutics for the treatment of multiple sclerosis: hopes and hazards
Clemens Warnke1, Bernd C Kieseier, Hans-Peter Hartung
1Department of Neurology, Medical Faculty, Heinrich-Heine-University Düsseldorf, Moorenstrasse 5, 40225 Duesseldorf, Germany.
Abstract:
Multiple sclerosis (MS), the most common cause of neurological disability in young adults, represents the prototypic inflammatory autoimmune disorder of the central nervous system. Increased understanding of the immunopathological processes underlying this disease, advances in biotechnology, development of powerful magnetic resonance imaging technologies together with improvements in clinical trial design have translated into a variety of new and innovative therapeutic avenues. In this review, we will highlight recent therapeutic developments in MS and critically discuss new challenges associated with these new treatment options.
Related Concept Videos
Multiple Sclerosis l: Introduction
Microorganisms in Medicine and Therapeutics
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Mesenchymal Stem Cells
